ICU MEDICAL INC/DE
About ICU MEDICAL INC/DE
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $2.2B
- Net income
- $732.0K
- Total assets
- $4.1B
- Market cap
- $3.4B
- Gross margin
- 36.8%
- Operating margin
- 1.9%
- Net margin
- 0.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.2B
- Cost of revenue
- $1.4B
- Gross profit
- $822.0M
- Operating expenses
- $779.2M
- Operating income
- $42.8M
- Income tax
- $2.4M
- Net income
- $732.0K
- EPS (basic)
- $0.03
- EPS (diluted)
- $0.03
Balance sheet
- Total assets
- $4.1B
- Current assets
- $1.2B
- Total liabilities
- $1.9B
- Current liabilities
- $498.9M
- Shareholders’ equity
- $2.1B
Cash flow
- Operating cash flow
- $179.8M
- Investing cash flow
- $122.2M
- Financing cash flow
- -$311.5M
- Net cash flow
- -$603.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $3.4B
- P/E ratio
- 4582.7
- EPS (diluted)
- $0.03
- Shares outstanding
- 24.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 31, 1992
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $732.0K in FY2025.
- Revenue grew 70% from FY2021 to FY2025.
- Gross margin of 36.8%, net margin 0.0%.
- Trading 13% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 4582.7.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ICU MEDICAL INC/DE.
Write a review
News about ICU MEDICAL INC/DE
News & sentiment via Polygon.io
